CL2003002731A1 - Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe - Google Patents

Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe

Info

Publication number: CL2003002731A1
Authority: CL; Chile
Prior art keywords: compound; enfe; kinasa; aurora; quinazoline
Prior art date: 2002-12-24

Application number

CL200302731A

Other languages

English (en)

Inventor

Nicola Murdoch Mortlock Heron

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-24

Filing date

2003-12-22

Publication date

2005-01-07

2003-12-22 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-01-07 Publication of CL2003002731A1 publication Critical patent/CL2003002731A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CL200302731A 2002-12-24 2003-12-22 Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe CL2003002731A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02293238		2002-12-24
EP03291315		2003-06-02

Publications (1)

Publication Number	Publication Date
CL2003002731A1 true CL2003002731A1 (es)	2005-01-07

Family

ID=32683824

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200302731A CL2003002731A1 (es)	2002-12-24	2003-12-22	Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe

Country Status (29)

Country	Link
US (4)	US7528121B2 (es)
EP (2)	EP1578755B1 (es)
JP (3)	JP4422102B2 (es)
KR (1)	KR101010299B1 (es)
AR (2)	AR042668A1 (es)
AT (2)	ATE370958T1 (es)
AU (1)	AU2003290313B2 (es)
BR (1)	BRPI0317717B8 (es)
CA (1)	CA2511613C (es)
CL (1)	CL2003002731A1 (es)
CY (2)	CY1107775T1 (es)
DE (2)	DE60315892T2 (es)
DK (2)	DK1578755T3 (es)
ES (2)	ES2290529T3 (es)
IL (2)	IL169112A (es)
IS (2)	IS2504B (es)
MX (1)	MXPA05006918A (es)
MY (2)	MY136174A (es)
NO (2)	NO335193B1 (es)
NZ (1)	NZ540698A (es)
PL (2)	PL221490B1 (es)
PT (2)	PT1578755E (es)
RU (3)	RU2350611C1 (es)
SA (1)	SA04240504B1 (es)
SI (2)	SI1578755T1 (es)
TW (2)	TWI336327B (es)
UA (1)	UA83814C2 (es)
UY (1)	UY28149A1 (es)
WO (1)	WO2004058781A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA04006260A (es) *	2001-12-24	2005-03-31	Astrazeneca Ab	Derivados de quinazolina sustituidos como inhibidores de cinasas aurora.
WO2004058752A1 (en) *	2002-12-24	2004-07-15	Astrazeneca Ab	Quinazoline compounds
EP1578755B1 (en) *	2002-12-24	2007-08-22	AstraZeneca AB	Phosphonooxy quinazoline derivatives and their pharmaceutical use
BRPI0409427A (pt) *	2003-04-16	2006-04-18	Astrazeneca Ab	composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
CA2526285A1 (en) *	2003-05-15	2004-12-23	Arqule, Inc.	Inhibitors of p38 and methods of using the same
ES2308182T3 (es) *	2003-06-02	2008-12-01	Astrazeneca Ab	Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer.
US7572914B2 (en)	2003-12-19	2009-08-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US7550598B2 (en)	2004-08-18	2009-06-23	Takeda Pharmaceutical Company Limited	Kinase inhibitors
CA2581516C (en)	2004-10-12	2013-06-11	Astrazeneca Ab	Quinazoline derivatives
JP2008515961A (ja) *	2004-10-12	2008-05-15	アストラゼネカアクチボラグ	癌に対する使用のためのキナゾリン誘導体
EP1812439B2 (en)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinase inhibitors
EP1809636A1 (en) *	2004-10-19	2007-07-25	Arqule, Inc.	Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
UY30183A1 (es)	2006-03-02	2007-10-31	Astrazeneca Ab	Derivados de quinolina
EP2013218A2 (en) *	2006-04-17	2009-01-14	Arqule, Inc.	Raf inhibitors and their uses
GB0609621D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Novel co-crystal
GB0609617D0 (en)	2006-05-16	2006-06-21	Astrazeneca Ab	Process & intermediate
GB0609619D0 (en) *	2006-05-16	2006-06-21	Astrazeneca Ab	Combination
BRPI0719883A2 (pt)	2006-10-09	2015-05-05	Takeda Pharmaceutical	Inibidores de quinase
EP2262796A1 (en) *	2008-03-04	2010-12-22	Vitae Pharmaceuticals, Inc.	Aurora kinase inhibitors
US20110033461A1 (en) *	2008-03-12	2011-02-10	Vladimir Ratushny	Combination Therapy for the Treatment of Cancer
JP5502072B2 (ja)	2008-04-30	2014-05-28	ナショナルヘルスリサーチインスティテューツ	オーロラキナーゼ阻害剤としての縮合二環式ピリミジン化合物
EP2291376A2 (en) *	2008-07-03	2011-03-09	Merck Patent GmbH	Naphthyridininones as aurora kinase inhibitors
MX2011005788A (es) *	2008-12-05	2011-06-21	Arqule Inc	Inhibidores raf y sus usos.
US7863325B2 (en)	2008-12-11	2011-01-04	Axcentua Pharmaceuticals Ab	Crystalline genistein sodium salt dihydrate
AU2009324489B2 (en)	2008-12-11	2015-11-12	Axcentua Pharmaceuticals Ab	Crystalline forms of genistein
AU2009330727B2 (en)	2008-12-22	2016-07-28	Millennium Pharmaceuticals, Inc.	Combination of Aurora kinase inhibitors and anti-CD20 antibodies
SG192769A1 (en)	2011-03-04	2013-09-30	Glaxosmithkline Ip No 2 Ltd	Amino-quinolines as kinase inhibitors
TWI547494B (zh)	2011-08-18	2016-09-01	葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之胺基喹唑啉類
AR092530A1 (es)	2012-09-13	2015-04-22	Glaxosmithkline Llc	Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092529A1 (es)	2012-09-13	2015-04-22	Glaxosmithkline Llc	Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AU2014216178B2 (en)	2013-02-15	2018-06-28	KALA BIO, Inc.	Therapeutic compounds and uses thereof
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN105189462B (zh)	2013-02-20	2017-11-10	卡拉制药公司	治疗性化合物和其用途
TWI630203B (zh) *	2013-02-21	2018-07-21	葛蘭素史克智慧財產發展有限公司	做為激酶抑制劑的喹唑啉類
PE20160930A1 (es) *	2013-09-16	2016-09-03	Astrazeneca Ab	Nanoparticulas polimericas terapeuticas y metodos para su elaboracion y uso.
AU2014342042B2 (en)	2013-11-01	2017-08-17	KALA BIO, Inc.	Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
EP3076963A4 (en)	2013-12-06	2017-09-13	Millennium Pharmaceuticals, Inc.	Combination of aurora kinase inhibitors and anti-cd30 antibodies
EP3324976A4 (en)	2015-07-21	2019-03-27	Millennium Pharmaceuticals, Inc.	ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
CN109688818A (zh)	2016-09-08	2019-04-26	卡拉制药公司	治疗化合物的晶型及其用途
EP3509422A4 (en)	2016-09-08	2020-05-20	Kala Pharmaceuticals, Inc.	CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CA3036340A1 (en)	2016-09-08	2018-03-15	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
PL3678668T3 (pl)	2017-09-08	2024-06-03	The Board Of Trustees Of The Leland Stanford Junior University	Inhibitory enpp1 i ich zastosowanie w leczeniu nowotworu
WO2019195658A1 (en)	2018-04-05	2019-10-10	Dana-Farber Cancer Institute, Inc.	Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es)	2018-09-09	2020-03-12	Fundacio Privada Institut De Recerca De La Sida - Caixa	Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en)	2019-08-26	2021-03-04	Dana-Farber Cancer Institute, Inc.	Use of heparin to promote type 1 interferon signaling
WO2021094379A1 (en)	2019-11-12	2021-05-20	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) *	2019-12-11	2022-05-17	苏州美诺医药科技有限公司	新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en)	2020-06-24	2021-12-30	Astrazeneca Uk Limited	Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en)	2021-03-10	2022-09-15	Astrazeneca Ab	Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL89029A (en)	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en)	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
DE69222637T2 (de)	1991-05-10	1998-02-26	Rhone Poulenc Rorer Int	Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU2737295A (en)	1994-06-09	1996-01-04	Glaxo Group Limited	Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (es)	1994-11-12	1997-12-01	Zeneca Ltd
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
US6716575B2 (en)	1995-12-18	2004-04-06	Sugen, Inc.	Diagnosis and treatment of AUR1 and/or AUR2 related disorders
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
IL124728A (en)	1995-12-18	2007-06-03	Sugen Inc	AURORA – 1 and AURORA – 2 proteins
BR9707495A (pt)	1996-02-13	1999-07-27	Zeneca Ltd	Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
AU719327B2 (en)	1996-03-05	2000-05-04	Astrazeneca Ab	4-anilinoquinazoline derivatives
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
GB9714249D0 (en)	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
ZA986732B (en)	1997-07-29	1999-02-02	Warner Lambert Co	Irreversible inhibitiors of tyrosine kinases
DE69925141T2 (de) *	1998-10-08	2006-04-27	Astrazeneca Ab	Chinazolin derivate
GB9900334D0 (en)	1999-01-07	1999-02-24	Angiogene Pharm Ltd	Tricylic vascular damaging agents
GB9900752D0 (en)	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
PL354323A1 (en)	1999-09-21	2004-01-12	Astrazeneca Ab	Quinazoline derivatives and their use as pharmaceuticals
GB9922171D0 (en)	1999-09-21	1999-11-17	Zeneca Ltd	Chemical compounds
IL152682A0 (en)	2000-05-31	2003-06-24	Astrazeneca Ab	Indole derivatives with vascular damaging activity
ES2305081T3 (es)	2000-06-28	2008-11-01	Astrazeneca Ab	Derivados de quinozolina sustituidos y su uso como inhibidores.
KR20030022264A (ko)	2000-07-07	2003-03-15	앤지오젠 파마슈티칼스 리미티드	신생 혈관 형성 억제제인 콜치놀 유도체
WO2002004434A1 (en)	2000-07-07	2002-01-17	Angiogene Pharmaceuticals Limited	Colchinol derivatives as vascular damaging agents
WO2002016351A1 (en) *	2000-08-18	2002-02-28	Cor Therapeutics, Inc.	Quinazoline derivatives as kinase inhibitors
US6610677B2 (en)	2000-09-15	2003-08-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
AU2002350105A1 (en)	2001-06-21	2003-01-08	Ariad Pharmaceuticals, Inc.	Novel quinazolines and uses thereof
GB0124299D0 (en) *	2001-10-10	2001-11-28	Astrazeneca Ab	Crystal structure of enzyme and uses thereof
MXPA04006260A (es)	2001-12-24	2005-03-31	Astrazeneca Ab	Derivados de quinazolina sustituidos como inhibidores de cinasas aurora.
WO2004058752A1 (en) *	2002-12-24	2004-07-15	Astrazeneca Ab	Quinazoline compounds
EP1578755B1 (en) *	2002-12-24	2007-08-22	AstraZeneca AB	Phosphonooxy quinazoline derivatives and their pharmaceutical use
BRPI0409427A (pt) *	2003-04-16	2006-04-18	Astrazeneca Ab	composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo

2003
- 2003-12-22 EP EP03782672A patent/EP1578755B1/en not_active Expired - Lifetime
- 2003-12-22 UA UAA200507294A patent/UA83814C2/ru unknown
- 2003-12-22 AT AT03782672T patent/ATE370958T1/de active
- 2003-12-22 DK DK03782672T patent/DK1578755T3/da active
- 2003-12-22 SI SI200330965T patent/SI1578755T1/sl unknown
- 2003-12-22 NZ NZ540698A patent/NZ540698A/en not_active IP Right Cessation
- 2003-12-22 DK DK07009390T patent/DK1847539T3/da active
- 2003-12-22 DE DE60315892T patent/DE60315892T2/de not_active Expired - Lifetime
- 2003-12-22 RU RU2007121850/04A patent/RU2350611C1/ru active
- 2003-12-22 MY MYPI20034944A patent/MY136174A/en unknown
- 2003-12-22 PT PT03782672T patent/PT1578755E/pt unknown
- 2003-12-22 MX MXPA05006918A patent/MXPA05006918A/es active IP Right Grant
- 2003-12-22 US US10/539,220 patent/US7528121B2/en active Active
- 2003-12-22 EP EP07009390A patent/EP1847539B1/en not_active Expired - Lifetime
- 2003-12-22 ES ES03782672T patent/ES2290529T3/es not_active Expired - Lifetime
- 2003-12-22 CA CA2511613A patent/CA2511613C/en not_active Expired - Lifetime
- 2003-12-22 PL PL377680A patent/PL221490B1/pl unknown
- 2003-12-22 DE DE60328735T patent/DE60328735D1/de not_active Expired - Lifetime
- 2003-12-22 PT PT07009390T patent/PT1847539E/pt unknown
- 2003-12-22 CL CL200302731A patent/CL2003002731A1/es unknown
- 2003-12-22 BR BRPI0317717A patent/BRPI0317717B8/pt not_active IP Right Cessation
- 2003-12-22 JP JP2005509716A patent/JP4422102B2/ja not_active Expired - Lifetime
- 2003-12-22 KR KR1020057012015A patent/KR101010299B1/ko not_active Expired - Lifetime
- 2003-12-22 WO PCT/GB2003/005613 patent/WO2004058781A1/en not_active Ceased
- 2003-12-22 PL PL412704A patent/PL223998B1/pl unknown
- 2003-12-22 AT AT07009390T patent/ATE438644T1/de active
- 2003-12-22 RU RU2005123485/04A patent/RU2357971C2/ru active
- 2003-12-22 SI SI200331673T patent/SI1847539T1/sl unknown
- 2003-12-22 MY MYPI20071321A patent/MY147761A/en unknown
- 2003-12-22 AU AU2003290313A patent/AU2003290313B2/en not_active Expired
- 2003-12-22 ES ES07009390T patent/ES2329623T3/es not_active Expired - Lifetime
- 2003-12-23 AR ARP030104824A patent/AR042668A1/es active IP Right Grant
- 2003-12-23 TW TW092136601A patent/TWI336327B/zh not_active IP Right Cessation
- 2003-12-23 TW TW099134275A patent/TWI393710B/zh not_active IP Right Cessation
- 2003-12-23 UY UY28149A patent/UY28149A1/es not_active Application Discontinuation
2004
- 2004-02-18 SA SA04240504A patent/SA04240504B1/ar unknown
2005
- 2005-06-09 IL IL169112A patent/IL169112A/en active IP Right Grant
- 2005-06-13 NO NO20052855A patent/NO335193B1/no not_active IP Right Cessation
- 2005-07-20 IS IS7948A patent/IS2504B/is unknown
2007
- 2007-05-16 AR ARP070102117A patent/AR057753A2/es not_active Application Discontinuation
- 2007-06-13 RU RU2007121850/04K patent/RU2007121850A/ru unknown
- 2007-06-28 JP JP2007169891A patent/JP4906608B2/ja not_active Expired - Lifetime
- 2007-08-09 IL IL185176A patent/IL185176A/en active IP Right Grant
- 2007-10-24 CY CY20071101369T patent/CY1107775T1/el unknown
2008
- 2008-02-13 IS IS8714A patent/IS2884B/is unknown
- 2008-10-15 JP JP2008265949A patent/JP4503090B2/ja not_active Expired - Lifetime
2009
- 2009-04-28 US US12/431,165 patent/US8268841B2/en not_active Expired - Lifetime
- 2009-10-13 CY CY20091101054T patent/CY1109479T1/el unknown
2012
- 2012-08-21 US US13/590,662 patent/US9018191B2/en not_active Expired - Lifetime
2013
- 2013-11-01 NO NO20131444A patent/NO335446B1/no not_active IP Right Cessation
2015
- 2015-03-18 US US14/661,657 patent/US9567358B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2007326862A (ja)	2007-12-20
UA83814C2 (ru)	2008-08-26
BR0317717A (pt)	2005-11-22
AU2003290313B2 (en)	2007-05-10
EP1578755A1 (en)	2005-09-28
PT1847539E (pt)	2009-10-06
AR042668A1 (es)	2005-06-29
AR057753A2 (es)	2007-12-19
EP1847539B1 (en)	2009-08-05
DK1847539T3 (da)	2009-11-09
TW200510342A (en)	2005-03-16
SI1578755T1 (sl)	2007-12-31
ES2329623T3 (es)	2009-11-27
NO20052855D0 (no)	2005-06-13
IL169112A0 (en)	2009-02-11
BRPI0317717B8 (pt)	2021-05-25
DE60315892D1 (de)	2007-10-04
US20140162984A1 (en)	2014-06-12
TWI336327B (en)	2011-01-21
US7528121B2 (en)	2009-05-05
SA04240504B1 (ar)	2008-04-01
RU2005123485A (ru)	2006-03-10
NO20052855L (no)	2005-08-03
KR101010299B1 (ko)	2011-01-25
HK1080481A1 (en)	2006-04-28
CA2511613A1 (en)	2004-07-15
DK1578755T3 (da)	2007-11-12
HK1111417A1 (en)	2008-08-08
CY1109479T1 (el)	2014-08-13
RU2357971C2 (ru)	2009-06-10
PL377680A1 (pl)	2006-02-06
NO335193B1 (no)	2014-10-20
IL185176A0 (en)	2007-12-03
ATE370958T1 (de)	2007-09-15
JP4906608B2 (ja)	2012-03-28
MY147761A (en)	2013-01-31
TWI393710B (zh)	2013-04-21
CY1107775T1 (el)	2013-06-19
IS2884B (is)	2014-06-15
US9018191B2 (en)	2015-04-28
TW201102369A (en)	2011-01-16
SA04240504A (ar)	2005-12-03
MY136174A (en)	2008-08-29
PT1578755E (pt)	2007-10-19
IS7948A (is)	2005-07-20
JP2009046514A (ja)	2009-03-05
JP4503090B2 (ja)	2010-07-14
ES2290529T3 (es)	2008-02-16
IS8714A (is)	2008-02-13
PL412704A1 (pl)	2015-10-12
NO20131444L (no)	2005-08-03
UY28149A1 (es)	2004-07-30
JP2006512418A (ja)	2006-04-13
AU2003290313A1 (en)	2004-07-22
MXPA05006918A (es)	2005-08-18
JP4422102B2 (ja)	2010-02-24
IL185176A (en)	2011-10-31
US20060116357A1 (en)	2006-06-01
US20100069412A1 (en)	2010-03-18
BRPI0317717B1 (pt)	2017-12-19
CA2511613C (en)	2012-10-02
DE60315892T2 (de)	2008-08-14
EP1578755B1 (en)	2007-08-22
PL223998B1 (pl)	2016-11-30
IS2504B (is)	2009-04-15
PL221490B1 (pl)	2016-04-29
IL169112A (en)	2010-12-30
DE60328735D1 (de)	2009-09-17
RU2007121850A (ru)	2008-12-20
US9567358B2 (en)	2017-02-14
NZ540698A (en)	2008-05-30
US8268841B2 (en)	2012-09-18
WO2004058781A1 (en)	2004-07-15
SI1847539T1 (sl)	2010-01-29
EP1847539A1 (en)	2007-10-24
ATE438644T1 (de)	2009-08-15
KR20050088333A (ko)	2005-09-05
RU2350611C1 (ru)	2009-03-27
US20150307534A1 (en)	2015-10-29
NO335446B1 (no)	2014-12-15

Publication	Publication Date	Title
CL2003002731A1 (es)	2005-01-07	Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
CL2007003244A1 (es)	2008-04-04	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2009000349A1 (es)	2010-02-19	Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2008002295A1 (es)	2009-03-27	Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2004000930A1 (es)	2005-03-18	Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
CL2007003299A1 (es)	2008-08-22	Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2004001069A1 (es)	2005-04-01	Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
CL2007003352A1 (es)	2008-07-04	Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen
BRPI0816553A2 (pt)	2017-07-18	"composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
BRPI0510177B8 (pt)	2021-05-25	composto, composição farmacêutica e uso do mesmo
CL2007001882A1 (es)	2008-02-08	Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
CL2007001630A1 (es)	2008-02-08	Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2007002234A1 (es)	2008-06-13	Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
AR068369A1 (es)	2009-11-11	Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
BRPI0605921B8 (pt)	2021-05-25	compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
CL2007001870A1 (es)	2008-06-13	Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
BRPI0815079A2 (pt)	2015-02-03	Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
CL2009000281A1 (es)	2009-06-26	Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
CL2008002430A1 (es)	2009-10-16	Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2007001881A1 (es)	2008-02-08	Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
WO2006119283A3 (en)	2009-04-16	Anti-odor compositions and therapeutic use
CL2008001721A1 (es)	2008-12-19	Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
CL2007002578A1 (es)	2008-07-04	Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
CL2007002384A1 (es)	2008-01-18	Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.